Trial Profile

A Single-Arm, Open-Label, Dose-Escalation and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FXS887 in Patients With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jan 2026 New trial record
03 Dec 2025 According to Shanghai Fosun Pharmaceutical media release, company received approval from the National Medical Products Administration (NMPA) to conduct clinical trials of FXS0887 tablets (project code, hereinafter referred to as "FXS0887") for advanced malignant solid tumors. Fosun Pharma Industry plans to conduct Phase I clinical trials of FXS0887 in China when conditions permit.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com